LBRX Lb Pharmaceuticals announces accelerated timing of topline results from the phase 3 Nova-2 trial of Lb-102 in schizophrenia
LBRX Lb Pharmaceuticals announces accelerated timing of topline results from the phase 3 Nova-2 trial of Lb-102 in schizophrenia
Story updates
12:01:23 PM UTC
SquawkNews
LBRX - LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
LBRX - LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia